A novel early onset phenotype in a zebrafish model of merosin deficient congenital muscular dystrophy

PLoS One. 2017 Feb 27;12(2):e0172648. doi: 10.1371/journal.pone.0172648. eCollection 2017.

Abstract

Merosin deficient congenital muscular dystrophy (MDC1A) is a severe neuromuscular disorder with onset in infancy that is associated with severe morbidities (particularly wheelchair dependence) and early mortality. It is caused by recessive mutations in the LAMA2 gene that encodes a subunit of the extracellular matrix protein laminin 211. At present, there are no treatments for this disabling disease. The zebrafish has emerged as a powerful model system for the identification of novel therapies. However, drug discovery in the zebrafish is largely dependent on the identification of phenotypes suitable for chemical screening. Our goal in this study was to elucidate novel, early onset abnormalities in the candyfloss (caf) zebrafish, a model of MDC1A. We uncovered and characterize abnormalities in spontaneous coiling, the earliest motor movement in the zebrafish, as a fully penetrant change specific to caf mutants that is ideal for future drug testing.

MeSH terms

  • Animals
  • Animals, Genetically Modified
  • Disease Models, Animal*
  • Heterozygote
  • Laminin / genetics*
  • Laminin / metabolism
  • Muscle, Skeletal / metabolism
  • Muscular Dystrophies / genetics*
  • Muscular Dystrophies / metabolism
  • Mutation
  • Phalloidine / biosynthesis
  • Phenotype
  • Zebrafish / metabolism

Substances

  • Laminin
  • laminin alpha2, zebrafish
  • Phalloidine

Supplementary concepts

  • Muscular dystrophy congenital, merosin negative